MedPath

Breath Volatile Organic Compounds Patterns of Lung Transplant Patients With Chronic Lung Allograft Dysfunction

Completed
Conditions
Chronic Lung Allograft Dysfunction (CLAD)
Interventions
Other: Collection of exhaled breath volatile organic compounds
Registration Number
NCT02836938
Lead Sponsor
Prof. Dr. Jens Hohlfeld
Brief Summary

It's the aim of this study to clarify, whether the non-invasive assessment of breath can serve as a novel clinical tool to assist in the diagnosis of CLAD. If different stages of BOS can be discriminated by the level of certain VOCs than there would also be a potential to actually predict the development at an early stage and would enable an earlier intervention.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
75
Inclusion Criteria
  • Outpatient bilateral lung transplant recipients including combined transplants
Exclusion Criteria
  • Active Smoking Oxygen therapy Infection with multi or pan-resistant bacteria

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
SevereCollection of exhaled breath volatile organic compoundsSevere chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 3
ControlCollection of exhaled breath volatile organic compoundsBronchiolitis obliterans syndrome (BOS), stage 0
MildCollection of exhaled breath volatile organic compoundsMild chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 1-2
Primary Outcome Measures
NameTimeMethod
Concentration of exhaled breath volatile organic compoundsone sample will be collected between 6 month and 20 years after lung transplantation
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hannover Medical School

🇩🇪

Hannover, Germany

© Copyright 2025. All Rights Reserved by MedPath